Being immune deficient doesn’t mean hope deficient. That’s why we at Enzyvant are committed to the Pediatric congenital athymia patient community. The congenital athymia, or complete lack of a thymus, associated with Pediatric congenital athymia results in severe primary immunodeficiency and is almost uniformly fatal if untreated. Pediatric congenital athymia is a lead focus for our research and drug development. On Rare Disease Day 2018, we are launching Re:GenerationHope, a disease awareness and fundraising initiative, to thank and celebrate the Pediatric congenital athymia babies and families who have enabled research advancement. We have three goals:
- Spread awareness of Pediatric congenital athymia, a rare disease that few people besides the diagnosed know of
- Raise funds for the primary immunodeficiency patient advocacy organizations who support the Pediatric congenital athymia patient community
- Share hope and support for those diagnosed with Pediatric congenital athymia
Re:GenerationHope is about building community, and we ask you to raise awareness for this disease using the hashtag #ReGenerationHope across Twitter and Facebook. We will also be donating to two primary immunodeficiency patient advocacy groups: the Immune Deficiency Foundation (IDF) and the Jeffrey Modell Foundation (JMF). In honor of the Pediatric congenital athymia babies and families who have participated in clinical trials at Duke Children’s Hospital, we will donate $1 each to IDF and JMF for every post, share, and retweet using the hashtag #ReGenerationHope. The more you share, the more we donate.
To see what else we’re doing on Rare Disease Day 2018, follow us @Enzyvant.
For every Facebook post, Facebook share, tweet, and retweet using the hashtag #ReGenerationHope on Rare Disease Day 2018 (February 28, 2018 ET), Enzyvant will donate $1 to the Immune Deficiency Foundation and $1 to the Jeffrey Modell Foundation up to $20,000 per organization. Enzyvant will donate a minimum of $5,000 to each organization.